Braveheart Bio

Q2 FY2026 EarningsBraveheart Bio (BRVE) reported a Q2 2026 net loss of $15.0M, significantly outperforming the consensus estimate of a $31.35M loss. EPS GAAP of -$2.51 was also better than the mean expectation of -$3.17. As a pre-revenue clinical-stage biotech, the variance is primarily driven by lower-than-anticipated operating expenses despite a sharp YoY ramp-up in R&D to support the Phase 3 LIONHEART-HCM trial. Post-quarter, the company significantly bolstered its liquidity via an August IPO, raising approximately $404.5M in net proceeds, providing a substantial runway for its pivotal HCM programs through 2027.